Search

Displaying results 811 - 820 of 2483 in total
  1. Drug

    Epaminurad

    go.drugbank.com/drugs/DB18973
    Investigational

    Epaminurad is under investigation in clinical trial NCT05815901 (A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 Substrates
  2. Drug

    Bersacapavir

    go.drugbank.com/drugs/DB19035
    Investigational

    Bersacapavir is under investigation in clinical trial NCT03365947 (Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV)).

    Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 Substrates
  3. Drug

    p-Boronophenylalanine

    go.drugbank.com/drugs/DB19158
    Investigational

    p-Boronophenylalanine is under investigation in clinical trial NCT00039572 (Boron Neutron Capture Therapy in Treating Patients With Glioblastoma Multiforme or Melanoma Metastatic to the Brain).

    Synonyms: L-p-boronophenylalanine
  4. Drug

    Human placenta hydrolysate

    go.drugbank.com/drugs/DB19297
    Investigational

    Categories: Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  5. Drug

    Vamorolone

    go.drugbank.com/drugs/DB15114
    ApprovedInvestigational

    Vamorolone is a novel and fully synthetic glucocorticoid developed by Santhera Pharmaceuticals. It is used to manage inflammation and immune dysregulation in patients with Duchenne muscular dystrophy (DMD), a neuromuscular disorder chara...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inducers
  6. Drug

    Pozelimab

    go.drugbank.com/drugs/DB15218
    ApprovedInvestigational

    [A261120] Pozelimab is a human, monoclonal immunoglobulin G4<sup>P</sup> antibody against the terminal complement protein C5.

  7. Drug

    Olorofim

    go.drugbank.com/drugs/DB15245
    Investigational

    Olorofim is under investigation in clinical trial NCT03340597 (Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects).

    Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Substrates
  8. Drug

    Crizanlizumab

    go.drugbank.com/drugs/DB15271
    ApprovedInvestigational

    Crizanlizumab is a humanized IgG2 monoclonal antibody used to reduce the frequency of vaso-occlusive crises in patients with sickle cell disease. Sickle cell disease is a genetically inherited condition prevalent in the Middle East, Afri...

  9. Drug

    Risdiplam

    go.drugbank.com/drugs/DB15305
    ApprovedInvestigational

    Risdiplam is an orally bioavailable mRNA splicing modifier used for the treatment of spinal muscular atrophy (SMA). It increases systemic SMN protein concentrations by improving the efficiency of SMN2 gene transcription. This mechanism o...

    Categories: Cytochrome P-450 Substrates, P-glycoprotein substrates
  10. Drug

    Ubrogepant

    go.drugbank.com/drugs/DB15328
    ApprovedInvestigational

    [erenumab], [fremanezumab], [galcanezumab]) have also been approved in recent years.[A189207] Ubrogepant was approved by Health Canada on November 10, 2022.

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates